Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders' Equity

v3.22.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Convertible Preferred Stock
Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   0 8,349      
Beginning balance at Dec. 31, 2020 $ 4,434 $ 0 $ 8 $ 204,376 $ (847) $ (199,103)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (3,670)         (3,670)
Issuance of common stock under:            
Equity financing, net (in shares)     3,980      
Equity financing, net 35,360   $ 4 35,356    
Exercise of warrants (in shares)     300      
Exercise of warrants 3,878   $ 1 3,877    
Matching contribution to 401(k) plan (in shares)     26      
Matching contribution to 401(k) plan 152     152    
Stock-based compensation expense 356     356    
Foreign currency translation adjustments 465       465  
Ending balance (in shares) at Mar. 31, 2021   0 12,655      
Ending balance at Mar. 31, 2021 40,975 $ 0 $ 13 244,117 (382) (202,773)
Beginning balance (in shares) at Dec. 31, 2021   0 12,693      
Beginning balance at Dec. 31, 2021 37,219 $ 0 $ 13 246,090 (17) (208,867)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (4,620)         (4,620)
Issuance of common stock under:            
Matching contribution to 401(k) plan (in shares)     68      
Matching contribution to 401(k) plan 176     176    
Equity incentive plan (in shares)     83      
Stock-based compensation expense 499     499    
Foreign currency translation adjustments 212       212  
Ending balance (in shares) at Mar. 31, 2022   0 12,844      
Ending balance at Mar. 31, 2022 $ 33,486 $ 0 $ 13 $ 246,765 $ 195 $ (213,487)